Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot
CPT®
90712

CPT® Code 90712
Deleted

Official Description

Poliovirus vaccine, (any type[s]) (OPV), live, for oral use

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The poliovirus vaccine, identified by CPT® Code 90712, is a live vaccine administered orally to provide active immunity against poliovirus. Unlike immune globulins, which offer short-term, passive immunity, vaccines like this one stimulate the recipient's immune system to produce its own antibodies. This process involves exposing the immune system to a weakened form of the poliovirus, which is known as an attenuated virus. The immune system responds by generating antibodies that can recognize and combat the actual virus if encountered in the future. The primary purpose of this vaccine is to prevent poliomyelitis, a potentially debilitating disease caused by the poliovirus. The oral poliovirus vaccine (OPV) is specifically designed to trigger a robust immune response while ensuring that the individual does not develop the disease itself, as the live virus is not virulent enough to cause illness. It is important to note that this code specifically reports the use of any type of live poliovirus vaccine for oral administration, distinguishing it from other types of poliovirus vaccines, such as the inactivated poliovirus vaccine (IPV), which is administered via subcutaneous or intramuscular routes and is reported under CPT® Code 90713. The focus of this code is solely on the vaccine product itself, rather than the administration or clinical context in which it is used.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The poliovirus vaccine (CPT® Code 90712) is indicated for the prevention of poliomyelitis, a viral disease that can lead to paralysis and other serious complications. The vaccine is recommended for individuals, particularly children, who are at risk of exposure to the poliovirus, especially in areas where the virus is still present or where outbreaks may occur. The administration of this vaccine is crucial in maintaining herd immunity and preventing the spread of poliovirus within communities.

  • Prevention of Poliomyelitis The primary indication for the poliovirus vaccine is to prevent poliomyelitis, a disease caused by the poliovirus that can result in paralysis and other severe health issues.
  • At-Risk Populations The vaccine is particularly indicated for children and individuals in areas where poliovirus is endemic or where outbreaks have been reported.

2. Procedure

The administration of the poliovirus vaccine involves several key procedural steps to ensure proper delivery and effectiveness of the vaccine. Each step is critical to achieving the desired immune response.

  • Step 1: Preparation Prior to administration, the healthcare provider must prepare the vaccine according to the manufacturer's instructions. This includes checking the expiration date, ensuring proper storage conditions, and shaking the vaccine vial gently to mix the contents if necessary.
  • Step 2: Patient Assessment The healthcare provider should assess the patient’s medical history to confirm that there are no contraindications to receiving the vaccine. This includes checking for any previous allergic reactions to vaccines or components of the poliovirus vaccine.
  • Step 3: Administration The vaccine is administered orally, typically using a dropper or a syringe without a needle. The patient is instructed to swallow the vaccine, which contains the live attenuated virus. It is important to ensure that the entire dose is ingested to achieve the desired immune response.
  • Step 4: Post-Administration Monitoring After administration, the patient should be monitored for a short period to observe for any immediate adverse reactions. This is a standard practice to ensure patient safety and to address any potential side effects promptly.

3. Post-Procedure

Following the administration of the poliovirus vaccine, patients are generally advised to observe for any side effects, which may include mild fever or gastrointestinal symptoms. These reactions are typically short-lived and indicate that the immune system is responding to the vaccine. It is important for healthcare providers to inform patients about the expected outcomes and to schedule follow-up vaccinations as part of the complete immunization schedule. Additionally, patients should be educated on the importance of completing the vaccination series to ensure full protection against poliomyelitis.
Short Descr ORAL POLIOVIRUS VACCINE
Medium Descr POLIOVIRUS VACCINE ANY LIVE ORAL
Long Descr Poliovirus vaccine, (any type[s]) (OPV), live, for oral use
Status Code Excluded from Physician Fee Schedule by Regulation
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
APC Status Indicator Items and Services Packaged into APC Rates
Type of Service (TOS) 1 - Medical Care
Berenson-Eggers TOS (BETOS) O1G - Immunizations/Vaccinations
MUE Not applicable/unspecified.
CCS Clinical Classification 228 - Prophylactic vaccinations and inoculations
Date
Action
Notes
2016-01-01 Deleted Deleted
2008-01-01 Changed Code description changed.
Pre-1990 Added Code added.
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"